Three additional studies are ongoing to evaluate if the anti-PD-1 antibody Nivolumab has a beneficial effect for the treatment of AML, either as monotherapy or in combination with chemotherapy or HMAs. The gene discussed is PDCD1; the disease is acute myeloid leukemia.